Rapport Therapeutics (RAPP) Competitors $9.60 -0.24 (-2.44%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$9.60 0.00 (0.00%) As of 09:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RAPP vs. VERA, SPRY, IRON, MESO, IMCR, TVTX, INDV, EWTX, OCUL, and CALTShould you be buying Rapport Therapeutics stock or one of its competitors? The main competitors of Rapport Therapeutics include Vera Therapeutics (VERA), ARS Pharmaceuticals (SPRY), Disc Medicine (IRON), Mesoblast (MESO), Immunocore (IMCR), Travere Therapeutics (TVTX), Indivior (INDV), Edgewise Therapeutics (EWTX), Ocular Therapeutix (OCUL), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry. Rapport Therapeutics vs. Vera Therapeutics ARS Pharmaceuticals Disc Medicine Mesoblast Immunocore Travere Therapeutics Indivior Edgewise Therapeutics Ocular Therapeutix Calliditas Therapeutics AB (publ) Rapport Therapeutics (NASDAQ:RAPP) and Vera Therapeutics (NASDAQ:VERA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings, media sentiment and community ranking. Is RAPP or VERA more profitable? Rapport Therapeutics' return on equity of 0.00% beat Vera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rapport TherapeuticsN/A N/A N/A Vera Therapeutics N/A -50.13%-39.50% Do analysts rate RAPP or VERA? Rapport Therapeutics presently has a consensus price target of $32.67, suggesting a potential upside of 240.28%. Vera Therapeutics has a consensus price target of $64.67, suggesting a potential upside of 199.52%. Given Rapport Therapeutics' higher possible upside, research analysts clearly believe Rapport Therapeutics is more favorable than Vera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rapport Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Vera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 3 Strong Buy rating(s) 3.20 Does the MarketBeat Community believe in RAPP or VERA? Vera Therapeutics received 38 more outperform votes than Rapport Therapeutics when rated by MarketBeat users. However, 75.00% of users gave Rapport Therapeutics an outperform vote while only 66.13% of users gave Vera Therapeutics an outperform vote. CompanyUnderperformOutperformRapport TherapeuticsOutperform Votes375.00% Underperform Votes125.00% Vera TherapeuticsOutperform Votes4166.13% Underperform Votes2133.87% Do insiders and institutionals hold more shares of RAPP or VERA? 99.2% of Vera Therapeutics shares are held by institutional investors. 21.7% of Vera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has higher valuation & earnings, RAPP or VERA? Vera Therapeutics is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRapport TherapeuticsN/AN/A-$34.79M-$13.84-0.69Vera TherapeuticsN/AN/A-$95.99M-$2.75-7.85 Does the media favor RAPP or VERA? In the previous week, Vera Therapeutics had 1 more articles in the media than Rapport Therapeutics. MarketBeat recorded 12 mentions for Vera Therapeutics and 11 mentions for Rapport Therapeutics. Vera Therapeutics' average media sentiment score of 1.05 beat Rapport Therapeutics' score of 0.56 indicating that Vera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vera Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryVera Therapeutics beats Rapport Therapeutics on 9 of the 15 factors compared between the two stocks. Remove Ads Get Rapport Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RAPP vs. The Competition Export to ExcelMetricRapport TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$350.36M$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-0.696.8121.7017.82Price / SalesN/A225.96377.7294.61Price / CashN/A65.6738.1534.64Price / BookN/A5.866.464.00Net Income-$34.79M$141.86M$3.20B$247.23M7 Day Performance6.90%4.38%2.77%1.44%1 Month Performance-8.66%-12.76%-8.60%-6.26%1 Year PerformanceN/A-11.13%10.40%0.59% Rapport Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAPPRapport Therapeutics1.6783 of 5 stars$9.60-2.4%$32.67+240.3%N/A$350.36MN/A-0.69N/AShort Interest ↑VERAVera Therapeutics2.9009 of 5 stars$21.50-4.1%$64.67+200.8%-53.6%$1.43BN/A-8.2440Positive NewsSPRYARS Pharmaceuticals3.1645 of 5 stars$14.47+3.0%$31.00+114.2%+62.2%$1.42B$89.15M-28.3790Gap DownIRONDisc Medicine2.5588 of 5 stars$40.27+4.0%$93.80+132.9%+35.4%$1.39BN/A-10.1230MESOMesoblast2.6532 of 5 stars$10.74+5.9%$18.00+67.6%+108.3%$1.36B$5.67M0.0080Positive NewsGap UpIMCRImmunocore2.1889 of 5 stars$26.92+1.2%$63.73+136.7%-50.8%$1.33B$310.20M-28.34320Analyst ForecastNews CoverageTVTXTravere Therapeutics2.5538 of 5 stars$14.83+2.3%$32.08+116.3%+135.9%$1.32B$233.18M-3.62460Analyst ForecastINDVIndivior3.7771 of 5 stars$9.44+3.6%$15.00+58.9%-53.9%$1.30B$1.19B-26.971,164Short Interest ↓Positive NewsEWTXEdgewise Therapeutics2.0915 of 5 stars$12.33+8.0%$40.38+227.5%-21.0%$1.29BN/A-8.2260OCULOcular Therapeutix3.4274 of 5 stars$7.57+6.5%$16.38+116.3%-3.5%$1.20B$63.72M-5.73230Gap DownCALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180 Remove Ads Related Companies and Tools Related Companies VERA Competitors SPRY Competitors IRON Competitors MESO Competitors IMCR Competitors TVTX Competitors INDV Competitors EWTX Competitors OCUL Competitors CALT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RAPP) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RAPP Stock Free RAPP Stock Alerts